doi: 10.1128/AAC.33.8.1395.
Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir
Affiliations
- PMID: 2552912
- PMCID: PMC172665
- DOI: 10.1128/AAC.33.8.1395
Item in Clipboard
Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir
Antimicrob Agents Chemother.
1989 Aug.
Erratum in
- Antimicrob Agents Chemother 1989 Oct;33(10):1827
Abstract
Two mutants defective in herpes simplex virus-encoded ribonucleotide reductase activity exhibited the novel phenotype of hypersensitivity to acyclovir, aphidicolin, and to a lesser extent, phosphonoacetic acid. These results have implications for acyclovir resistance and the development of drugs that potentiate acyclovir action by inhibition of viral ribonucleotide reductase.
Similar articles
-
2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir.Proc Natl Acad Sci U S A. 1989 Feb;86(3):1051-5. doi: 10.1073/pnas.86.3.1051. Proc Natl Acad Sci U S A. 1989. PMID: 2536930 Free PMC article.
-
Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.Antimicrob Agents Chemother. 1992 May;36(5):934-7. doi: 10.1128/AAC.36.5.934. Antimicrob Agents Chemother. 1992. PMID: 1324641 Free PMC article.
-
Single mutations at many sites within the DNA polymerase locus of herpes simplex viruses can confer hypersensitivity to aphidicolin and resistance to phosphonoacetic acid.J Gen Virol. 1984 Jan;65 ( Pt 1):1-17. doi: 10.1099/0022-1317-65-1-1. J Gen Virol. 1984. PMID: 6319564
-
[Antiviral resistance of herpes simplex virus and varicella-zoster virus].Nihon Rinsho. 2007 Feb 28;65 Suppl 2 Pt. 1:480-6. Nihon Rinsho. 2007. PMID: 17455667 Review. Japanese. No abstract available.
-
[Contribution of the laboratory in case of resistance to acyclovir of herpes simplex and varicella zoster virus].Ann Biol Clin (Paris). 2003 Jan-Feb;61(1):33-40. Ann Biol Clin (Paris). 2003. PMID: 12604384 Review. French.
Cited by
-
Herpes Simplex Oncolytic Viral Therapy for Malignant Glioma and Mechanisms of Delivery.World Neurosurg. 2025 Feb;194:123595. doi: 10.1016/j.wneu.2024.123595. Epub 2025 Jan 23. World Neurosurg. 2025. PMID: 39710201 Free PMC article. Review.
-
Gene therapy for malignant glioma.Mol Cell Ther. 2014 Jul 8;2:21. doi: 10.1186/2052-8426-2-21. eCollection 2014. Mol Cell Ther. 2014. PMID: 26056588 Free PMC article. Review.
-
Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.Antimicrob Agents Chemother. 1998 Jul;42(7):1629-35. doi: 10.1128/AAC.42.7.1629. Antimicrob Agents Chemother. 1998. PMID: 9660995 Free PMC article.
-
Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses.Front Oncol. 2017 Sep 26;7:229. doi: 10.3389/fonc.2017.00229. eCollection 2017. Front Oncol. 2017. PMID: 29018771 Free PMC article. Review.
-
Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: selection and characterization of mutant isolates.J Virol. 1996 Feb;70(2):787-93. doi: 10.1128/JVI.70.2.787-793.1996. J Virol. 1996. PMID: 8551616 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
